IQVIA Holdings Inc. (NYSE: IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, announced it has entered into an agreement to acquire certain discovery services assets from Charles River Laboratories. This transformative acquisition marks a significant expansion of IQVIA’s drug discovery capabilities and reinforces its commitment to providing comprehensive, end-to-end solutions for pharmaceutical and biotechnology clients.
Strategic Acquisition Details and Asset Portfolio
The acquisition encompasses five specialized sites focused on providing a comprehensive range of in vitro drug discovery services. These facilities are equipped with established laboratory-based New Approach Methodologies (NAMs) and feature a sophisticated small molecule AI platform designed to accelerate discovery programs and support the growing demand for non-animal research methods.
The acquired assets represent decades of accumulated expertise and scientific rigor. Collectively, they are underpinned by more than 20 years of curated scientific and operational data, as well as extensive therapeutic expertise across multiple disease areas. This wealth of institutional knowledge and proven track record provides immediate value to IQVIA clients seeking to advance their drug development programs.
Since their inception, these assets have demonstrated a substantial impact on the drug discovery landscape. The portfolio has enabled over 100 molecules to enter clinical trials, with several advancing to commercial approval. This proven capability underscores the quality and effectiveness of the platforms being acquired.
This acquisition will meaningfully strengthen our ability to support clients earlier in the R&D lifecycle and complements our existing translational and clinical development capabilities.
“Integrating these assets with our existing capabilities creates an industry-leading drug discovery platform with a track record of advancing discovery programs into clinical development.
David Morris
Read More: IQVIA Outpaces Expectations in 2025, Doubles Down on Healthcare-Grade AI Strategy for 2026
By acquiring these assets, IQVIA positions itself to support clients throughout the complete drug development journey. The combination creates a vertically integrated platform that enables pharmaceutical and biotech companies to initiate their research programs with IQVIA and continue through clinical development, translational science, and commercial launch. This comprehensive approach reduces friction in the development process and enhances efficiency.
Enhanced Non-Animal Testing and AI-Driven Innovation
The modern pharmaceutical industry faces increasing regulatory and ethical pressure to reduce reliance on animal testing in drug discovery and development. The acquired assets directly address this critical market need through advanced methodologies and innovative technologies.
New Approach Methodologies (NAMs) at the Core of Innovation
The New Approach Methodologies integrated into the acquired platforms represent cutting-edge alternatives to traditional animal-based testing. These laboratory-based approaches utilize advanced in vitro techniques, including cell culture systems, tissue engineering, and organ-on-a-chip technologies. Such methods not only align with evolving regulatory frameworks and ethical standards but also accelerate the discovery process by enabling more rapid testing of compound libraries and mechanism-of-action studies.
The NAMs portfolio has proven effective across multiple therapeutic areas and represents years of refinement and validation. Their incorporation into IQVIA’s broader capabilities enables clients to meet regulatory requirements while reducing time and costs associated with preclinical research.
Small Molecule AI Platform for Accelerated Discovery
The small molecule AI platform included in the acquisition represents a significant technological asset. This proprietary system leverages machine learning and artificial intelligence to predict molecular properties, optimize compound structures, and identify promising candidates for further development. By analyzing the extensive historical dataset embedded in the platform, researchers can make more informed decisions about which compounds to prioritize, reducing the number of iterations required to identify viable drug candidates.
The AI platform’s integration with the laboratory-based NAMs creates a powerful synergy. Researchers can rapidly generate computational predictions and immediately validate them through experimental work, creating a feedback loop that accelerates the discovery process significantly.
Building an Integrated, End-to-End Drug Discovery Platform
The acquisition represents more than a simple asset purchase; it embodies a strategic vision for comprehensive drug development services. By integrating these acquired assets with IQVIA’s existing drug discovery capabilities, the company creates a fully integrated platform that spans the entire drug development continuum.
This integration enables several significant advantages for IQVIA’s clientele:
Seamless Transition Between Discovery and Development Phases. Clients can work with a single provider throughout their development journey, eliminating the friction and miscommunication that often occurs when transferring programs between different vendors. A unified team approach ensures consistent data quality, methodology alignment, and strategic objectives throughout the program.
Comprehensive Data Integration. The combination of discovery-stage research with translational and clinical capabilities enables better data integration and deeper insights. Findings from early-stage discovery can inform clinical trial design, while clinical observations can suggest new avenues for future research programs.
Accelerated Timelines. By consolidating services under one roof, IQVIA can optimize the transition between discovery and development phases, reducing the time required to move promising compounds into human trials.
Enhanced Resource Allocation. A unified platform allows for more sophisticated resource allocation and prioritization. Programs with the highest potential for success can be rapidly scaled, while struggling programs can receive additional support or be appropriately deprioritized.
Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN
The FDA has granted traditional approval to Novartis' Fabhalta (iptacopan) — the first complement inhibitor shown to significantly slow kidney function decline in adults with […]
LIPFENDRA FDA Approval: Merck’s Enlicitide Becomes First Oral PCSK9 Inhibitor to Lower LDL-C
The LIPFENDRA FDA approval makes Merck's enlicitide the first once-daily oral PCSK9 inhibitor cleared to lower LDL-C in adults with hypercholesterolemia, including HeFH. Phase 3 […]
GSK Nuvalent Acquisition: GSK Completes $10.6 Billion Nuvalent Acquisition, Expanding Lung Cancer Pipeline
GSK has completed its $10.6 billion acquisition of Nuvalent, Inc., gaining three targeted lung cancer therapies, including zidesamtinib and neladalkib, both currently under FDA review […]
Transaction Timeline and Expected Impact
The transaction is expected to close during the second quarter of 2026, subject to customary closing conditions and regulatory approvals. While the financial terms of the deal were not publicly disclosed, the acquisition represents a significant investment in IQVIA’s drug discovery infrastructure and capabilities.
The timing of the acquisition is particularly strategic. The life sciences industry is experiencing renewed momentum following a period of contraction during late 2023 and 2024. Pharmaceutical and biotech companies have reported increased project proposals and declining contract cancellations, indicating stronger demand for research services. Additionally, biotech firms have experienced improved funding access since early 2025 after facing financial constraints in the post-pandemic era.
Last Modified:
